Skip to main content
Cyclerion Therapeutics, Inc. logo

Cyclerion Therapeutics, Inc. — Investor Relations & Filings

Ticker · CYCN ISIN · US23255M1053 US Manufacturing
Open in API
Filings indexed 338 across all filing types
Latest filing 2026-04-30 Annual Report
Country US United States of America
Listing US CYCN

About Cyclerion Therapeutics, Inc.

https://www.cyclerion.com/

Cyclerion Therapeutics, Inc. is a biopharmaceutical company dedicated to advancing personalized therapeutic approaches for neuropsychiatric disorders. The company's primary focus is on developing a treatment for people with Treatment-Resistant Depression (TRD). Its lead program utilizes a method that combines generic anesthetics with a personalized, biofeedback-driven device. This approach is designed to reset dysregulated brainwave patterns by tailoring the therapy to each patient's specific biological needs, offering a new option for individuals who have not responded to traditional treatments.

Recent filings

Filing Released Lang Actions
10-K/A - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Annual Report FY 2025
2026-04-30 English
S-4 - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
Regulatory Filings
2026-04-18 English
8-K - Cyclerion Therapeutics, Inc. (0001755237) (Filer)
M&A Activity Classification · 100% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a detailed merger agreement between Cyclerion Therapeutics, Inc. and Korsana Biosciences, Inc., including terms of the merger, stock exchange ratios, voting proposals, and conditions for closing. It also references a forthcoming Form S-4 registration statement that will include a proxy statement for shareholder approval. The document is not a full annual or quarterly report, nor is it an earnings release or audit report. It is not a proxy solicitation itself but mentions that a proxy statement will be filed later. The primary purpose is to announce the entry into a material definitive agreement related to a merger. According to the filing definitions, announcements and documents related to merger proposals or takeover bids fall under the category "M&A Activity" (Code: TAR). The document length is substantial and contains detailed merger terms, consistent with an M&A announcement rather than a brief notice or regulatory filing. Therefore, the correct classification is M&A Activity (TAR).
2026-04-01 English
8-K Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text indicates it is a short filing (3532 characters) reporting a press release about a product development update and formation of a clinical advisory board. It explicitly states that the press release is attached as an exhibit and is not considered filed for certain regulatory purposes. There are no financial statements or detailed financial data included, nor is this an annual or quarterly report. The document is primarily an announcement of a press release and not the report itself. According to the rules, such short filings that announce or attach other documents without substantive financial data should be classified as Regulatory Filings (RNS).
2026-02-17 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or agreements. The text describes the entry into a material definitive agreement (a Collaboration and Option Agreement) and references a press release and investor presentation attached as exhibits. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is primarily an announcement of a material agreement and related disclosures, typical of a Capital/Financing Update or similar event. Given the nature of the content—announcement of a collaboration agreement and related investor presentation—the most appropriate classification is Capital/Financing Update (CAP).
2026-01-06 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The content describes a milestone event related to a license agreement and clinical trial initiation, which is an 'Other Event' under Item 8.01. It does not contain financial statements or detailed financial analysis, nor is it a full annual or quarterly report. It is not an earnings release or management discussion. The document is a regulatory announcement of a material event, fitting the category of Regulatory Filings (RNS). The document length is 4736 characters, which is typical for an 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS) with high confidence.
2025-12-01 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.